MN1 and acute myeloid leukemia: However, patients with high BAALC or MN1 expression at diagnosis—both markers repeatedly published to confer inferior prognosis in chemotherapy-consolidated AML patients—might benefit from an allogeneic HSCT as consolidation therapy.